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Abstract
Background: Predicting the function of a protein is one of the major challenges in the post-genomic era where a large
number of protein sequences of unknown function are accumulating rapidly. Lectins are the proteins that specifically
recognize and bind to carbohydrate moieties present on either proteins or lipids. Cancerlectins are those lectins that play
various important roles in tumor cell differentiation and metastasis. Although the two types of proteins are linked, still
there is no computational method available that can distinguish cancerlectins from the large pool of non-cancerlectins.
Hence, it is imperative to develop a method that can distinguish between cancer and non-cancerlectins.
Results: All the models developed in this study are based on a non-redundant dataset containing 178
cancerlectins and 226 non-cancerlectins in which no two sequences have more than 50% sequence similarity. We
have applied the similarity search based technique, i.e. BLAST, and achieved a maximum accuracy of 43.25%. The
amino acids compositional analysis have shown that certain residues (e.g. Leucine, Proline) were preferred in
cancerlectins whereas some other (e.g. Asparatic acid, Asparagine) were preferred in non-cancerlectins. It has been
found that the PROSITE domain “Crystalline beta gamma” was abundant in cancerlectins whereas domains like
“SUEL-type lectin domain” were found mainly in non-cancerlectins. An SVM-based model has been developed to
differentiate between the cancer and non-cancerlectins which achieved a maximum Matthew’s correlation
coefficient (MCC) value of 0.32 with an accuracy of 64.84%, using amino acid compositions. We have developed a
model based on dipeptide compositions which achieved an MCC value of 0.30 with an accuracy of 64.84%.
Thereafter, we have developed models based on split compositions (2 and 4 parts) and achieved an MCC value of
0.31, 0.32 with accuracies of 65.10% and 66.09%, respectively. An SVM model based on Position Specific Scoring
Matrix (PSSM), generated by PSI-BLAST, was developed and achieved an MCC value of 0.36 with an accuracy of
68.34%. Finally, we have integrated the PROSITE domain information with PSSM and developed an SVM model that
has achieved an MCC value of 0.38 with 69.09% accuracy.
Conclusion: BLAST has been found inefficient to distinguish between cancer and non-cancerlectins. We analyzed
the protein sequences of cancer and non-cancerlectins and identified interesting patterns. We have been able to
identify PROSITE domains that are preferred in cancer and non-cancerlectins and thus provided interesting insights
into the two types of proteins. The method developed in this study will be useful for researchers studying
cancerlectins, lectins and cancer biology. The web-server based on the above study, is available at http://www.
imtech.res.in/raghava/cancer_pred/
Background
Basically ‘Lectins’ d e r i v e df r o mt h eL a t i nw o r d“legere“
which means “to select”, are the biomolecules that speci-
fically recognize and bind to carbohydrates moieties pre-
sent on other proteins e.g. glycoproteins or lipids e.g.
glycolipids [1]. Lectins have been known to be involved
in numerous biological events e.g. host-pathogen inter-
actions, cell-cell recognition, complement activation
pathways, cell cycle regulation, apoptosis etc. Most lec-
tins are highly specific and selective in recognizing the
sugar moieties present on other proteins and bind to
them reversibly and non-covalently without inducing
any change in the bound carbohydrates [2]. These glyco-
proteins are generally classified into five groups based
on the monosaccharides for which they exhibit the
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galactose/N-acetylgalactosamine, N-acetylglucosamine,
fucose, and sialic acid [3]. Not only do lectins vary sig-
nificantly in their individualf u n c t i o n a lr o l e s ,b u tt h e y
are also diverse in their sequences, structures, binding
site architectures, quaternary structures, carbohydrate
affinities and specificities as well as in their potential
applications [4].
Cancerlectins are known to play various important
roles in cancer metastasis [5-7]. Several lines of evidence
implicate tumour cell lectins in cellular interactions such
as adhesion, cell growth, tumour cell differentiation,
metastasis and cellular infection [8,9]. The carbohydrate-
binding properties of lectins have been used to identify
tumour specific patterns in cancer cells, e.g. Helix Poma-
tia agglutinin binding is a useful prognostic indicator in
colorectal carcinoma [10-13]. Many lectins act as thera-
peutic lectins preferentially binding to cancer cell mem-
branes or their receptors causing cytotoxicity, apoptosis,
and inhibition of tumour growth [14]. Galectin is known
to play a role in infections as well as act as modulator of
tumour formation [9,15]. Galectin-3 is also known to
enhance the metastasis potential in human breast carci-
noma BT549 and in cancer apoptosis [16,17]. Mistletoe
lectins are known to induce apoptosis and telomerase
inhibition in Human A253 cancer cells [18].
Cancerlectins are known in terms of their source, class,
domain, fold class, quaternary structure and carbohydrate
specificity but the method to distinguish cancerlectins
from lectins or non-cancerlectin is still missing [19].
Results of similarity based techniques like BLAST and
FASTA are reliable only when the query sequence has
high sequence similarity with experimentally annotated
proteins [20-22]. In this study we systematically analyzed
cancerlectins and non-cancerlectins and developed a
method for their classification. We developed a Support
Vector Machine (SVM) based prediction method, Can-
cerPred for annotating cancerlectins on the basis of
amino acid composition and evolutionary information
using PSSMs, also having information about the specific
PROSITE domains found in the two types of proteins.
Methods
Datasets preparation
We downloaded 509 cancerlectin protein sequences from
cancerlectinDB database (http://proline.physics.iisc.ernet.
in/cgi-bin/cancerdb/input.cgi). After removing the pro-
teins having 100% sequence similarity using the CD-HIT
program, we obtained 385 sequences which formed the
positive dataset. For a negative dataset, we searched the
UniProt database (http://www.uniprot.org/) with the key-
word “lectin” and a total number of 1550 non-redundant
sequences were obtained. These were further filtered by
excluding the sequences containing the keywords “simi-
lar”, “fragment”, “putative” and “probable”, resulting in 891
lectin sequences. Seventy-one sequences were found to be
common to cancerlectins and lectins. These sequences
were then removed from lectins, reducing the number of
lectins to 820. To balance the datasets, a total of 385
sequences were randomly selected from the 820 lectin
sequences, to equalize the number of lectins to the initial
number of cancerlectins. Furthermore, to make non-
redundant datasets, the CD-HIT program was used at 50%
cutoff resulting in 178 cancerlectin and 226 non-cancer-
lectin sequences.
Subset sequences similarity
Although we had removed the 100% identical sequences
(71 from non-cancerlectins) and reduced the redun-
dancy up to 50% by using CD-HIT program, there were
chances of similarity between the two datasets (subsets).
To determine the similarity between cancer and non-
cancerlectins, we employed the BLAST tool using the
non-cancerlectins as test sequences against a database of
cancerlectins with an E value cut-off of 0.001. Out of
226 queries, a total of 145 hits were found, which con-
firmed that there was 64.15% sequence similarity
between non-cancerlectin and cancerlectin datasets.
Five-fold cross validation
Evaluation of newly-developed methods is a big challenge
in Bioinformatics. One of the most common techniques
for model evaluation is the Jack-knife test or leave-one
out cross-validation (LOOCV) [23-25]. In this technique,
one sequence is used for testing and the remaining ones
are used for training and the entire process is repeated in
such a way that each sequence is used once for testing.
Although it is one of the best techniques, it is very time
consuming and computationally demanding. Therefore,
we used the five-fold cross validation technique where
the whole set of sequences is randomly divided into five
sets. One set was used for testing and the remaining sets
were used for training. This process was repeated five
times in such a way that each test set was used once for
testing [26,27]. The final performance was the average of
the performances of the five sets.
Evaluation parameters
A set of parameters used to evaluate the performance of
the various methods is briefly described below.
1. Sensitivity
Sensitivity, or percentage coverage, is the percentage of
cancerlectins correctly predicted as “cancerlectins”.
Sensitivity =
TP
TP + FN
× 100
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Page 2 of 92. Specificity
Percentage of non-cancerlectins correctly predicted as
“non-cancerlectins”.
Speciﬁcity =
TN
TN + FP
× 100
3. Accuracy
Percentage of overall correctly predicted proteins (can-
cer and non-cancerlectins).
Accuracy =
TP + TN
TP + TN + FP + FN
× 100
4. Matthew’s correlation coefficient (MCC)
It is the statistical parameter used to assess the quality
of predictions and to correct the imbalance in the data.
It is calculated as follows:
MCC =
(TP × TN) − (FP × FN)

[(TP + FN)(TN + FP)(TP + FP)(TN + FN)]
Where TP is the number of correctly predicted pro-
teins in the positive dataset (cancerlectins) and TN is
the number of correctly predicted proteins in the nega-
tive dataset (non-cancerlectins), whereas FP is the num-
ber of wrongly predicted proteins in the positive dataset
and FN is the number of wrongly predicted proteins in
the negative dataset. For the evaluation of a new predic-
tion method MCC is considered the most robust para-
meter [28]. An MCC value of ‘1’ corresponds to a
prefect prediction and ‘0’ corresponds to a completely
random prediction. The limitation of the above-
described parameters is that they are threshold depen-
dent and require proper optimization for good perfor-
mance. We optimized these parameters manually and
selected the ones that gave the best performance. A
known threshold independent parameter is the Receiver
Operating Curve (ROC), which is a plot of the true
positive rate (TP/TP+FN) versus the false positive rate
(FP/FP+TN). The area under the curve (AUC) gives a
single value to evaluate the performance of a method.
We used the SigmaPlot 11.0 package for plotting the
ROC and calculating the AUC.
Support vector machine (SVM)
In this study we employed a highly successful machine
learning technique known as “Support Vector Machine”,
which is freely available at http://www.cs.cornell.edu/
People/tj/svm_light/. SVM is based on the structural
risk minimization principle of statistics learning theory
[29]. SVM is a set of related supervised learning meth-
ods used for classification and regression. It allowed us
to choose a number of parameters and kernels (e.g. Lin-
ear, Polynomial, Radial and sigmoid) or any other user-
defined kernel. We implemented the SVM
light version
6.01 package of SVM and learning was carried out by
using three (linear, polynomial and radial basis function)
kernels [30]. SVM takes a set of free vectors as input,
along with their output, which is used for training the
models. The trained model was used for the prediction
of non-annotated proteins [31]. In this work, we selected
the learning option -z (c) for classification purposes. The
SVM training was performed by optimizing various ker-
nel function parameters and the value of the regulariza-
tion parameter C. Preliminary tests showed that the
radial basis function (RBF) kernel provided better results
than other kernels. Therefore, the RBF kernel was used
for all the experiments. In the RBF kernel, we first opti-
mized parameters for gamma -g (0.0005 to 25), then
further optimized -c (-0.1 to 10) and finally the cost fac-
tor -j (1 to 10). In this study, we have used amino acid
composition, dipeptide composition, split compositions
(2 and 4), PSSM and PSSM-PROSITE domains as input
vectors in the SVM-based machine learning technique.
Protein features
The aim of calculating the composition of proteins is to
convert the variable length of protein sequences into
fixed length feature vectors. This is a crucial step
because the SVM machine learning technique requires
fixed length patterns.
Amino acid composition
Amino acid composition is the fraction of each of amino
acid in a protein sequence and provides vector of 20
dimensions. The SVM was provided with these 20
dimension vectors encapsulating the amino acid compo-
sition of proteins.
Dipeptide composition
Dipeptide composition was used to give global informa-
tion about each protein sequence and it gives a fixed
length pattern of 400 (20 × 20) features, one for each
dipeptide. The dipeptide composition incorporates the
fraction of amino acids as well as their local order i.e
order of amino acids in a protein sequence. In this way,
dipeptide composition is more informative than amino
acid composition.
Split amino acid composition
Split composition was used to detect conserved residues
or signal peptides in any terminal of the given protein
sequences [32-34]. In case of split amino acid composi-
tion, a sequence was divided into non-overlapping frag-
ments and amino acid composition of each fragment
was calculated independently. Thus, the dimension of
the final input vector was N × 20, where N is the num-
ber of fragments. In this study, proteins sequences
were divided into (i) two parts (N = 2) and (ii) four
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respectively.
Evolutionary information in the form of PSSM profiles
In this study, PSSM profiles were generated using PSI-
BLAST [29] to search a protein sequence against the
Swiss-Prot database with an E-value cutoff of 0.001. A
profile contains the probability of occurrence of each
amino acid and of insertion/deletion at every position
along the sequence. In this way, a PSSM was considered
as a measure of residue conservation at a given location.
This meant that evolutionary information for each
amino acid was encapsulated in a vector of 20 dimen-
sions, where the size of the PSSM for a protein with M
residues is 20 × M, where M is the length of the target
sequence and each element represents the frequency of
occurrence of each of the 20 amino acids [35].
Next, each element of the matrix (20 × M) was scaled
to the range of 0-1 using a sigmoid function. Further, in
order to obtain an input of fixed length, these normal-
ized PSSMs (20 × M) were used to generate a 400-
dimensional input vector by summing all rows in the
PSSM corresponding to each type of amino acid in the
sequence. Finally, each element in the input vector was
divided by the length of the protein sequence resulting
in a matrix of 400 (20 × 20) elements, which was used
as input vector for training the SVM.
PROSITE domains in cancer and non-cancerlectins
PROSITE is a database of families and domains found in
various proteins. During evolution, it is apparent that all
protein families conserve some portions of protein
sequences for efficient function and/or stability of three-
dimensional structure, which distinguish family mem-
bers from other proteins. InterProScan (IPRScan) is a
Perl based stand-alone tool that combines different pro-
tein signature-recognition methods into a single plat-
form [36]. PROSITE database is an integral part of
InterProScan. In this work, we searched and analyzed
PROSITE domains in cancer and non-cancerlectins
using ProfileScan method of InterProScan tool (version
4.4.1). Out of 178 cancer and 226 non-cancerlectins,
only 99 and 122 sequences were found to contain one
or more PROSITE domains, respectively. A total of 151
and 200 PROSITE domains were found in cancer and
non-cancerlectin dataset, respectively.
Results and discussion
Analysis of amino acid composition We analyzed the
amino acid composition of both cancer and non-can-
cerlectins proteins with the help of the Copid (http://
www.imtech.res.in/raghava/copid/) web server. As
s h o w ni nF i g u r e1 ,t h ef r e q u e n c yo fA l a ,G l u ,L e u ,P r o ,
Gln and Arg is higher in cancerlectins, while the fre-
quency of Asp, Phe, Ile, Lys, Asn, Thr, Val and Tyr is
higher in non-cancerlectins. There are major differ-
ences in composition of proline between cancerlectins
(high) and non-cancerlectins. This means that cancer
and non-cancerlectins can be distinguished on the
basis of their amino acid compositions. We also ana-
lyzed the statistical significance of the differences
observed in the amino acid composition, in terms of
p-value. We have noticed that Aspartic acid, Lysine,
Leucine, Asparagine, Proline and Arginine vary signifi-
cantly in their composition in cancer and non-cancer-
lectins, with p-values of 0.002, 0.007, 0.009, 0.003,
0.007 and 0.006 respectively [Additional file 1 Supple-
mentary Table S1].
Sequence similarity using BLAST
The most commonly used method for predicting the
function of a new protein is BLAST. It is a sequence
similarity based method and identifies regions/segments
in the query protein which are similar to the target
sequences. Thus, we have applied a BLAST-based
approach for discriminating between cancer and non-
cancerlectins at E-values ranging from 10
-1 to 10
-5.I n
this study, we used BLAST for predicting cancerlectin
proteins. We used a 5-fold cross-validation where four
sets of cancer and non-cancerlectins were used to create
a database whereas cancerlectins of the corresponding
fifth test set were searched against this database. This
process was repeated five times so the BLAST search
was performed once for each cancerlectin sequence. We
calculated the performance of BLAST in terms of per-
centage coverage, which indicated the number of correct
predictions in a test set. As shown in Table 1, we
achieved a maximum accuracy of 43.50% at an E-value
cutoff of 0.1. It is clear that BLAST is inefficient in dis-
tinguishing between cancer and non-cancerlectins. So
there is a need to develop models based on machine
learning technique to discriminate cancer and non-can-
cerlectins with a high accuracy [Additional file 1 Supple-
mentary Table S2].
Figure 1 Amino acid compositions of cancer and non-
cancerlectins. Comparative frequencies of 20 amino acids in
cancerlectins and non-cancerlectins.
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It can be inferred from the above analysis that the can-
cer and non-cancerlectins can be distinguished on the
basis of their composition. Hence, we developed a SVM-
based model using amino acid composition for predict-
ing cancer and non-cancerlectins and achieved a maxi-
mum MCC value of 0.32 using the RBF kernel. Previous
studies have shown that dipeptide compositions can be
successfully used for prediction of subcellular localiza-
tion of human protein [37,38]. It was observed that
methods based on dipeptide composition performed
better than amino acid composition based methods
because dipeptide also provided information about the
local order of the residues in addition to the amino acid
composition. Hence, in this study we developed an SVM
module using dipeptide composition and achieved a
maximum MCC value of 0.30 (with 64.84% accuracy)
using RBF kernel [Table 2]. We have further achieved
AUC values 0.82 and 0.85 for amino acid composition
and dipeptide composition respectively [Figure 2]. Since
the five-fold cross validation technique provides the
average accuracy over five sets, the standard error of
mean associated with the final accuracy have been cal-
culated (Additional file 1 supplementary Table S3, S4).
Split amino acid composition
Split amino acid compositions have been used success-
fully in the past to differentiate two types of proteins
with peptide signals at N or C-terminal. In order to uti-
lize the compositional biasness in the termini of cancer
and non-cancerlectins, we developed SVM modules
using split amino acid compositions. We used the split
(2 and 4) approach by dividing the protein into two and
four equal parts and calculating the amino acid compo-
sitions. This approach achieved MCC values of 0.31 and
0.32 (with accuracies 65.10% and 66.09%), respectively
[Table 2] (Additional file 1 supplementary Table S5, S6).
In terms of AUC, we achieved 0.80 and 0.79 values for
split-2 and split-4 compositions, respectively [Figure 2].
PSSM based SVM models
It has been shown in several studies the evolutionary
information obtained using multiple sequence alignment
provides more comprehensive information about a pro-
tein than a single sequence [31]. Earlier, PSSM matrices
having multiple sequence alignment information were
used for developing methods for alpha, beta and
gamma-turn prediction in protein sequences [39-41]. In
Table 1 Performance of BLAST on positive dataset of 178
cancerlectins at different E-values cutoffs
E-value Total
Proteins
Total
Hits
No
Hits
Correct
Hits
%
coverage
0.1 178 150 28 77 43.25
0.01 178 144 34 74 41.57
0.001 178 143 35 74 41.57
0.0001 178 142 36 74 41.57
0.00001 178 140 38 72 40.44
0.000001 178 140 38 72 40.44
Table 2 Performance of various modules of SVM developed by using Amino acid, dipeptide, split (2 and 4-part), PSSM
and PSSM-PROSITE domain based input features
Methods Threshold Sensitivity Specificity Accuracy MCC
Amino acid Composition -0.3 67.97 64.15 65.84 0.32
Dipeptide Composition -0.3 67.27 62.84 64.84 0.30
Split based Composition (2-part) -0.3 66.32 64.18 65.10 0.31
Split based Composition (4-part) -0.5 65.12 66.85 66.09 0.32
Position-Specific Scoring Matrix -0.2 67.92 68.57 68.34 0.36
PSSM with 14 PROSITE domains -0.1 68.00 69.90 69.09 0.38
(For details see Additional file 1 Tables S3 to S8)
Figure 2 ROC plots for various models. Performance of different
SVM modules (amino acid, dipeptide, split-2 & 4, PSSM, PSSM-
PROSITE) by Receiver Operating Characteristic (ROC) plot. In the
graph, “A” signifies the “AUC” value of the respective models.
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Firstly, we created a PSSM profile for each protein using
a PSI-BLAST search against the SwissProt database with
three iterations and with an E-value cutoff of 0.001. Sec-
ondly, we computed a vector of 400 dimensions from
the PSSM. Finally, an SVM model was developed from
the PSSM. The model achieved a maximum accuracy
value of 68.34% with an MCC value of 0.36 and an
AUC value of 0.80 [Figure 2]. This clearly demonstrates
that a PSSM provides more information than a single
sequence and is useful for predicting cancerlectins
[Table 2] (Additional file 1 supplementary Table S7).
PROSITE domains
We selected the 14 most distinguishable domains pre-
sent in either cancer or non-cancerlectins datasets: four
(PROSITE ids: PS50049, PS50217, PS50287 and
PS50915) in cancerlectins and ten (PROSITE ids:
PS51127, PS50927, PS50228, PS50068, PS50092,
PS50234, PS50853, PS50948, PS51115 and PS51117) in
non-cancerlectins [Table 3]. The domains “PS50915”
and “PS50049”, which correspond to “crystalline beta-
gamma” and “TNF family signature” respectively, were
exclusively found in cancerlectins. Out of the ten speci-
fic domains for non-cancerlectins, only PS50228 was
found once in cancerlectins.
SVM model using evolutionary information and PROSITE
domains
We generated a vector of 414 dimensions which con-
tains 400 PSSM features and 14 features for the selected
14 PROSITE domains. Finally, a SVM-based classifier
was developed using 414 features, 400 from PSSM pro-
file and 14 from domains, which achieved an accuracy
level of 69.09% with MCC value of 0.38 [Table 2]
(Additional file 1 supplementary Table S8). As shown in
Figure 2, the highest AUC value (0.95) is achieved with
the PSSM-PROSITE domain SVM.
Performance on random dataset
In this study, we built random datasets of cancer and
non-cancerlectins sequences by replacing 50% of cancer-
lectins into non-cancerlectins and vice-versa resulting in
two new datasets, each with 50% cancerlectins and non-
cancerlectins. We calculated the amino acid composition
and achieved an accuracy of 54.38% with an MCC value
of 0.09 [Additional file 1 Supplementary Table S10].
This shows that our original SVM models were built on
concrete information from amino acid, dipeptide, split
compositions and were capable of discriminating cancer
and non-cancerlectins with high accuracy.
Comparison with existing methods It is important to
compare the performance of a newly developed method
with that of other existing methods. In the past, a num-
ber of methods have been developed related to lectins e.
g. sugar-binding site in proteins, prediction of secondary
structure of legume lectins etc. but to the best of
author’s knowledge, there was no method that could
discriminate cancerlectins from lectins/non-cancerlec-
tins. We developed a novel method to distinguish can-
cerlectins from non-cancerlectins with high precision.
Web server We developed a webserver, CancerPred for
the prediction of cancerlectins which is freely available
at URL http://www.imtech.res.in/raghava/cancer_pred/.
It is developed under Solaris environment on a SUN
system, using CGI-PERL as programming language. This
server predicts whether a protein will be a cancerlectin
or a non-cancerlectin. The web server is user-friendly
and many options e.g. amino acid, dipeptide, split
Table 3 The PROSITE domain in 178 cancerlectins and 226 non-cancerlectins with their respective rate of occurrence
in two classes of proteins, with descriptions of domain name
PROSITE ID of the Domain No. of domains in cancerlectins No. of domains in lectins Class Description
PS50049 2 0 Cancerlectins TNF Family Signature
PS50217 2 0 Cancerlectins Basic Leucine Zipper domain
PS50287 2 0 cancerlectins SRCR domain signature
PS50915 7 0 cancerlectins Crystallin beta & gamma
PS51127 0 3 lectins Big-1(Bacterial Ig like-1)
PS50927 0 4 lectins Bulb-type lectin domain
PS50228 1 7 lectins SUEL-type lectin domain
PS50068 0 2 lectins LDL-receptor class-A domain
PS50092 0 2 lectins Thrombospondin Type-1
PS50234 0 2 lectins VWFA domain
PS50853 0 2 lectins Fibronectin type-III domain
PS50948 0 2 lectins PAN/apple domain
PS51115 0 2 lectins Laminin IV domain
PS51117 0 2 lectins Laminin-N terminal domain
The bold PROSITE domains show that these domains were reported in Cancerlectins only.
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submissions, the “submit1” option should be chosen
whereas for ‘PSSM’ and ‘PSSM-PROSITE’ based predic-
tions, the “submit2” option has to be selected, with sin-
gle sequence as input.
Discussion
Due to the rapid advancement in genomics and proteo-
mics, a tremendous amount of data is generated every
year. Functional annotation of all these proteins is not
possible by using only experimental approaches, as they
are laborious, costly and time-consuming. Therefore,
computational methods are required to fill this gap. The
functional annotation of all proteins is not possible at a
time. It is therefore important to concentrate on a single
class of functionally important proteins. Cancerlectins
represent an important class of proteins involved in var-
ious types of cancer metastasis, differentiation etc.
Therefore, it is very important to distinguish cancerlec-
tins from lectins (non-cancerlectins), which are growing
at a tremendous rate (~5280 lectin sequences annually).
In the past, predictions of (I) Sugar-binding sites on
proteins (II) Secondary structure of various legume lec-
tins have been reported [42-44]. The quaternary associa-
tions in legume lectins and mutagenesis and docking
studies have also been reported [45,46]; but there was
no method which could distinguish cancerlectins from
non-cancerlectins. We tried to predict cancerlectins
using existing techniques such as BLAST, obtaining
poor results, both in terms of accuracy and percentage
coverage. Thus, the BLAST-based prediction method is
unsuccessful in the case of cancerlectin prediction.
In this study, a systematic attempt has been made to
predict cancerlectins. In amino acid composition, we
collected information about the frequency of the 20
types of amino acids and used it in machine learning
technique. However, this approach provides information
only about the amino acid frequency, but not about the
local order of amino acids. To provide information
about both frequency and local order of amino acids,
dipeptide composition can be used as input. To check
the presence of any signal peptide present in cancerlec-
tins, we used the split amino acid composition in the
form of SVM input vectors. In our composition-based
SVM models, the overall accuracy of amino acid, dipep-
tide, split-based compositions were comparatively simi-
lar (~65%) with MCC values of 0.32, 0.30, 0.31
respectively. The PSSM-based evolutionary information
provides better information [47] hence we also made an
attempt to develop a method using evolutionary infor-
mation for predicting cancerlectins. The PSSM results
showed that the SVM model achieved an MCC value of
0.36 with 68.34% accuracy. This demonstrates that evo-
lutionary information is important for predicting
cancerlectin proteins. PROSITE-domains along with
PSSMs were used to train and develop the further SVM
modules to predict cancerlectins. A total of 14 PROSITE
domains (4 from cancerlectins and 10 from non-cancer-
lectins) were used for the model development. This
SVM module achieved the highest accuracy of 69.09%
with an MCC value of 0.38. Certain PROSITE domains,
e.g. PS50287 and PS50217 referring to “SRCR domain”
and “Basic Leucine Zipper domain” respectively were
exclusively found in cancerlectins. PS50927 and
PS50228 referred as “Bulb type lectin domain” and
“SUEL-type lectin domain” respectively was abundant in
non-cancerlectins. The Annexin (PROSITE domain -
PS00223), which is only found among cancerlectins in
the whole dataset, is involved in various biological pro-
cesses including various cancers e.g. prostate, colorectal,
breast and pancreatic cancer etc [48-51]. Crystalline
beta-gamma (PS50915) is the structural protein mainly
found in the lens of the vertebrate eye and it is reported
to play a role in oncogenesis of the lens [52]. Improve-
ments in prediction efficiency suggest that PROSITE
domain information has an important role in protein
discrimination, as cancerlectins and non-cancerlectins
differ in their PROSITE domain compositions.
Conclusion
This work attempts to predict cancerlectins, from a pool
of non-cancerlectins or simple lectins. We analyzed the
protein sequences of cancer and non-cancer lectins and
selected the distinguishable patterns e.g. amino acid,
dipeptide and split compositions. The patterns are based
on evolutionary information obtained by PSSM, and
PROSITE domain with PSSM. We used these patterns
as input features in SVM, a machine learning technique
used for classification and regression studies. We were
able to model an efficient classifier from PROSITE-
PSSM based approach. A web server CancerPred has
been developed on the SVM modules.
Additional material
Additional file 1: Supplementary Tables. Table S1: p-values for
compositional differences in cancerlectins and non-cancerlectins residues.
The amino acid compositions of cancer and non-cancerlectins and p-
value of composition difference in between the two types of proteins.
The bold values show the significant difference in composition of cancer
and non-cancerlectins, in term of p-values. Table S2: Performance of
BLAST on individual test sets of cancerlectins at E-value cutoff of 0.001.
The result of BLAST search on dataset of cancerlectins. The total hits
means the total number of hits found for a test set in BLAST search, no
hits is the number of proteins that did not get any hit whereas correct
hits shows the proteins whose top most hit belongs to the cancerlectin
class. The percentage coverage indicates the proteins that were
predicted as cancerlectins from the BLAST search. Table S3: The
performance of SVM model (Learning Parameter: -z c -t 2 -g 0.01 -c 0.5 -j
1) using Amino acid composition method. This table describes the
performance of amino acid composition based SVM model at each
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Page 7 of 9threshold (-1 to 1), providing sensitivity, specificity, accuracy and standard
error and MCC. Table S4: The performance of SVM model (Learning
Parameter: -z c -t 2 -g 0.001 -c 5 -j 1) using Dipeptide composition
method. This table describes the performance of dipeptide composition
based SVM model at each threshold (-1 to 1), providing sensitivity,
specificity, accuracy and standard error and MCC. Table S5: The
performance of SVM model (Learning Parameter: -z c -t 2 -g 0.001 -c 1 -j
1) using Split amino acid composition (2-part) method. This table
describes the performance of split amino acid (2-part) composition based
SVM model at each threshold (-1 to 1), providing sensitivity, specificity,
accuracy and standard error and MCC. Table S6: The performance of
SVM model (Learning Parameter: -z c -t 2 -g 0.0001 -c 1 -j 1) using Split
amino acid composition (4-part) method. This table describes the
performance of split amino acid (4-part) composition based SVM model
at each threshold (-1 to 1), providing sensitivity, specificity, accuracy and
standard error and MCC. Table S7: The performance of SVM model
(Learning Parameter: -z c -t 2 -g 7 -c 1 -j 1) using PSSM-based method.
This table describes the performance of PSSM based SVM model at each
threshold (-1 to 1), providing sensitivity, specificity, accuracy and standard
error and MCC. Table S8: The performance of SVM model (Learning
Parameter: -z c -t 2 -g 7 -c 5 -j 1) using PSSM-PROSITE Domain based
method. This table describes the performance of PSSM-PROSITE domain
based SVM model at each threshold (-1 to 1), providing sensitivity,
specificity, accuracy and standard error and MCC. Table S9: All reported
PROSITE domains in cancer and non-cancerlectins. All reported domains
reported in cancer and non-cancerlectins with their frequency of
occurrence. A total of 151 and 200 PROSITE domains were reported in
cancer and non-cancer lectins respectively. Table S10: The performance
of amino acid composition based SVM model (Learning Parameter: -z c -t
2 -g 0.01 -c 0.5 -j 1) using random dataset of cancer and non-
cancerlectins. This table describes the performance of amino acid
composition based SVM model at each threshold (-1 to 1), providing
sensitivity, specificity, accuracy and MCC.
List of abbreviations
AI: Artificial Intelligence; AUC: Area Under Curve; BLAST: Basic Local
Alignment Search Tool; MCC: Matthew’s Correlation Coefficient; PSI-BLAST:
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